Related Experiment Video
Updated: May 17, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Obesity pharmacotherapy: what is next?
Francheska Colon-Gonzalez1, Gilbert W Kim, Jieru E Lin
1Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, United States. Francheska.Colon-Gonzalez@jefferson.edu
Molecular Aspects of Medicine
|October 30, 2012
Summary
Obesity is a growing global health crisis. This review explores current and emerging anti-obesity drugs, offering a roadmap for safer, more effective weight management therapies.
Area of Science:
- Pharmacology
- Metabolic Disorders
- Public Health
Background:
- The global obesity epidemic has surged, with over a billion overweight adults by 2008.
- Obesity is linked to severe health issues including heart disease, diabetes, sleep apnea, and cancer.
- Current lifestyle interventions are insufficient for many, highlighting a critical need for effective anti-obesity therapeutics.
Purpose of the Study:
- To review existing and investigational anti-obesity drugs.
- To categorize these therapeutics by their biological targets and mechanisms of action.
- To provide insights into future anti-obesity drug development.
Main Methods:
- Literature review of current and emerging anti-obesity pharmacotherapies.
- Analysis of drug mechanisms targeting appetite regulation and metabolism.
- Synthesis of information to forecast future therapeutic trends.
Main Results:
- Historically, anti-obesity drugs have faced challenges with safety and efficacy.
- Advances in understanding appetite and metabolism biology enable new therapeutic strategies.
- A range of drugs targeting diverse pathways are currently available or in development.
Conclusions:
- New anti-obesity drugs offer potential for safer and more effective weight management.
- Understanding drug targets and mechanisms is crucial for therapeutic development.
- This review serves as a guide for future anti-obesity pharmacotherapy.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...